1. Diabetic kidney disease 2.0: the treatment paradigm shifts. Issue 11 (November 2019) Authors: Gilbert, Richard E Journal: Lancet Issue: Volume 7:Issue 11(2019) Page Start: 820 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Issue 12 (25th May 2018) Authors: Bugyei-Twum, Antoinette; Ford, Christopher; Civitarese, Robert; Seegobin, Jessica; Advani, Suzanne L; Desjardins, Jean-Francois; Kabir, Golam; Zhang, Yanling; Mitchell, Melissa; Switzer, Jennifer; Thai, Kerri; Shen, Vanessa; Abadeh, Armin; Singh, Krishna K; Billia, Filio; Advani, Andrew; Gilbert,... Journal: Cardiovascular research Issue: Volume 114:Issue 12(2018) Page Start: 1629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Understanding EMPA-REG OUTCOME. Issue 12 (December 2015) Authors: Gilbert, Richard E; Connelly, Kim A Journal: Lancet Issue: Volume 3:Issue 12(2015) Page Start: 930 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Heart failure: fatal, forgotten, and frequent in type 1 diabetes too. Issue 11 (November 2015) Authors: Gilbert, Richard E Journal: Lancet Issue: Volume 3:Issue 11(2015) Page Start: 832 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Issue 9982 (23rd May 2015) Authors: Gilbert, Richard E; Krum, Henry Journal: Lancet Issue: Volume 385:Issue 9982(2015) Page Start: 2107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Issue 5 (11th March 2020) Authors: Opingari, Erika; Verma, Subodh; Connelly, Kim A; Mazer, Cyril David; Teoh, Hwee; Quan, Adrian; Zuo, Fei; Pan, Yi; Bhatt, Deepak L; Zinman, Bernard; Leiter, Lawrence A; Yan, Andrew T; Cherney, David Z I; Gilbert, Richard E Journal: Nephrology dialysis transplantation Issue: Volume 35:Issue 5(2020) Page Start: 895 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD. (September 2016) Authors: Kepecs, David M; Yuen, Darren A; Zhang, Yanling; Thai, Kerri; Connelly, Kim A; Gilbert, Richard E Journal: Journal of the renin-angiotensin-aldosterone system Issue: Volume 17:Number 3(2016:Sep.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SGLT2 inhibitors: β blockers for the kidney?. Issue 10 (October 2016) Authors: Gilbert, Richard E Journal: Lancet Issue: Volume 4:Issue 10(2016) Page Start: 814 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Heart failure: fatal, forgotten, and frequent in type 1 diabetes too. Issue 11 (November 2015) Authors: Gilbert, Richard E Journal: Lancet Issue: Volume 3:Issue 11(2015) Page Start: 832 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗